Bill Text: HI HB1659 | 2020 | Regular Session | Amended


Bill Title: Relating To Health.

Spectrum: Partisan Bill (Democrat 1-0)

Status: (Enrolled - Dead) 2020-07-10 - Transmitted to Governor. [HB1659 Detail]

Download: Hawaii-2020-HB1659-Amended.html

HOUSE OF REPRESENTATIVES

H.B. NO.

1659

THIRTIETH LEGISLATURE, 2020

H.D. 3

STATE OF HAWAII

S.D. 1

 

 

 

 

 

A BILL FOR AN ACT

 

 

RELATING TO HEALTH.

 

 

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

 


     Section 1.  Chapter 328, Hawaii Revised Statutes, is amended by adding a new section to part I to be appropriately designated and to read as follows:

     "§328‑     Customized patient medication package.  (a)  A pharmacy may provide a customized patient medication package to any person; provided that:

     (1)  The pharmacy has obtained the consent of the patient, patient's caregiver, patient's guardian, or prescribing practitioner; provided that the consent may be communicated in writing, orally, or by electronic transmission; provided further that the format of the consent shall be identified on the prescription record required to be maintained under section 328-17.7;

     (2)  The consent is accompanied by the patient's current prescription; and

     (3)  The customized patient medication package meets the requirements of section 328-16.

     (b)  As used in this section, "customized patient medication package" means a package that is prepared by a pharmacist for a specific patient and contains one or more prescribed solid oral dosage forms."

     SECTION 2.  Section 329-14, Hawaii Revised Statutes, is amended to read as follows:

     "(b)  Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers, and salts is possible within the specific chemical designation:

     (1)  Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);

     (2)  Acetylmethadol;

     (3)  Allylprodine;

     (4)  Alphacetylmethadol (except levo-alphacetylmethadol, levomethadyl acetate, or LAAM);

     (5)  Alphameprodine;

     (6)  Alphamethadol;

     (7)  Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine);

     (8)  Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);

     (9)  Benzethidine;

    (10)  Betacetylmethadol;

    (11)  Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-phenylpropanamide);

    (12)  Beta-hydroxy-3-methylfentanyl (N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide);

    (13)  Betameprodine;

    (14)  Betamethadol;

    (15)  Betaprodine;

    (16)  Clonitazene;

    (17)  Dextromoramide;

    (18)  Diampromide;

    (19)  Diethylthiambutene;

    (20)  Difenoxin;

    (21)  Dimenoxadol;

    (22)  Dimepheptanol;

    (23)  Dimethylthiambutene;

    (24)  Dioxaphetyl butyrate;

    (25)  Dipipanone;

    (26)  Ethylmethylthiambutene;

    (27)  Etonitazene;

    (28)  Etoxeridine;

    (29)  Furethidine;

    (30)  Hydroxypethidine;

    (31)  Ketobemidone;

    (32)  Levomoramide;

    (33)  Levophenacylmorphan;

    (34)  3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide);

    (35)  3-methylthiofentanyl (N-[3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);

    (36)  Morpheridine;

    (37)  MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);

    (38)  Noracymethadol;

    (39)  Norlevorphanol;

    (40)  Normethadone;

    (41)  Norpipanone;

    (42)  Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-piperidinyl] propanamide;

    (43)  PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine;

    (44)  Phenadoxone;

    (45)  Phenampromide;

    (46)  Phenomorphan;

    (47)  Phenoperidine;

    (48)  Piritramide;

    (49)  Proheptazine;

    (50)  Properidine;

    (51)  Propiram;

    (52)  Racemoramide;

    (53)  Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-propanamide);

    (54)  Tilidine;

    (55)  Trimeperidine;

    (56)  N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl), its optical isomers, salts, and salts of isomers;

    (57)  N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl), its optical isomers, salts, and salts of isomers;

    (58)  N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide, (acetyl fentanyl), its optical, positional, and geometric isomers, salts, and salts of isomers;

    (59)  AH-7921 (3,4-dichloro-N-[(1-dimethylamino) cyclohexylmethyl]benzamide), its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers;

    (60)  N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide, its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers (Other names: Butyryl fentanyl);

    (61)  N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropionamide, its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers (Other names: beta-hydroxythiofentanyl);

    (62)  N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide, its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers (Other names: Furanyl fentanyl); [and]

    (63)  3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide, its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers (Other names: U-47700)[.];

    (64)  4-fluoroisobutyryl fentanyl or para-fluoroisobutyryl fenranyl [N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide];

    (65)  Acryl fentanyl or acryloylfentanyl [N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide]; and

    (66)  Ocfentanil [N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiprtidin-4-yl)acetamide]."

     SECTION 3.  Statutory material to be repealed is bracketed and stricken.  New statutory material is underscored.

     SECTION 4.  This Act shall take effect upon its approval.


 


 

Report Title:

Prescription Drugs; Pharmacy; Customized Patient Medication Packages; Schedule I Controlled Substances

 

Description:

Authorizes a pharmacy to provide a customized patient medication package to any person upon consent, with a valid prescription, and in compliance with labeling and dispensing requirements.  Adds certain substances to the list of Hawaii's Schedule I controlled substances.  (SD1)

 

 

 

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.

 

 

feedback